ABUS · CIK 0001447028
What Arbutus Biopharma Corp told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for ABUS. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- foreign clinical-trial data / FDA acceptancemedium
Arbutus conducts clinical trials in the US, Moldova, Taiwan, South Korea and Hong Kong; to the extent trials are not run under an IND, the FDA may not accept the foreign data, which could impede US regulatory approval.
“We are currently conducting our clinical trial in the United States, Moldova, Taiwan, South Korea, and Hong Kong. To the extent we do not conduct our clinical trials under an IND, the FDA may not accept data from such trials.”
SEC filing →As of 2026
Supplier concentration
- third-party CMO manufacturing (imdusiran, AB-101)medium
Arbutus has no internal large-scale manufacturing and relies entirely on third-party contract manufacturers to supply drug substance and drug product (including imdusiran and AB-101) for clinical trials and studies.
“We currently rely on third-party manufacturers to supply drug substance and drug products, including imdusiran and AB-101, for our ongoing and anticipated clinical trials and non-clinical studies. We currently have no plans to establish any large-scale internal manufacturing facilities for our product candidates”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Under the terms of the Moderna Settlement Agreement, Moderna will make an aggregate $950.0 million Noncontingent Settlement Payment to us and Genevant on or before July 8, 2026.”
Cited →Qilu Pharmaceutical Co., Ltd.
“Qilu was responsible for all costs related to developing, obtaining regulatory approval for, and commercializing imdusiran for the treatment or prevention of hepatitis B in Greater China and Taiwan.”
Cited →Genevant Sciences
“As of December 31, 2025, we owned approximately 16% of the common equity of Genevant and the carrying value of our investment in Genevant was zero. Our entitlement to receive future royalties or sublicensing revenue from Genevant was not impacted by the recapitalization.”
Cited →“Under the terms of this license agreement, we are entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% - 2.33%”
Cited →Acuitas Therapeutics
“a $1.7 million decrease in license royalty revenue from Alnylam and Acuitas related to lower sales of Alnylam's ONPATTRO in 2025 compared to 2024”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch